Ruxolitinib acts as a selective inhibitor of CaMKII-γ to impede the progression of Bortezomib-resistant multiple myeloma through AMPK-ULK1 axis-mediated autophagy pathway

Mingdi Wang(Qufu Normal University), Chaofeng Zhang(Peking University Shougang Hospital)
Research Square
October 10, 2025
Cited by 0


Related Papers

No related papers found

Powered by citation graph analysis